Reference

Use of b-lactamase inhibitors in disk tests to detect plasmid-mediated AmpC b-lactamases

Use of b-lactamase inhibitors in disk tests to detect plasmid-mediated AmpC b-lactamases. Black, Jennifer A.; Thomson, Kenneth S.; Pitout, Johann D. D. (Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, NE, USA).There are some reagents with their cas registry numbers 35607-66-0 and 80210-62-4 are used in this study. Journal of Clinical Microbiology, 42(5), 2203-2206 (English) 2004 American Society for Microbiology. CODEN: JCMIDW. ISSN: 0095-1137. DOCUMENT TYPE: Journal CA Section: 9 (Biochemical Methods) Seeking a simple disk test for detection of organisms producing plasmid-mediated AmpC b-lactamases, the authors evaluated the diagnostic utility of the b-lactamase inhibitors 48-1220 (Ro 48-1220) and LN-2-128. Using NCCLS disk methodol., inhibition zone diams. were detd. for five b-lactam antibiotics tested alone and in combination with 20 mg of either 48-1220 or LN-2-128. Using an increase of 34 mm in zone diam. in the presence of an inhibitor as a pos. test, cefotetan with LN-2-128 and 48-1220 was adequate for the detection of organisms producing plasmid-mediated AmpCs (specificity of 90% and sensitivity of 100%). .

Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity

Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity. Knothe, H.; Shah, P. M.; Eckardt, O. (Klin., J. W. Goethe Univ., Frankfurt W-6000/70, Germany). Infection (Munich), 19(5), 370-6 (English) 1991. CODEN: IFTNAL. ISSN: 0300-8126. DOCUMENT TYPE: Journal CA Section: 10 (Microbial, Algal, and Fungal Biochemistry) The antimicrobial activity of cefpodoxime, the active metabolite of the new cephalosporin ester cefpodoxime proxetil, in comparison to defixime, cefotiam, cefuroxime, and cefotaxime was detd.There are some reagents like 80210-62-4 is used in this study. against a broad spectrum of freshly isolated gram-pos. and gram-neg. bacterial strains. Cefpodoxime was inhibitory at concns. of ￡1 mg/L against 90% of the strains of Moraxella catarrhalis, Haemophilus influenzae, Escherichia coli (b-lactamase-neg. strains), Klebsiella spp., Serratia spp., Proteus mirabilis, Proteus vulgaris, Providencia spp., and Salmonella spp. This antimicrobial activity of cefpodoxime was generally superior to that of cefuroxime and similar to that of cefixime. Cefpodoxime was active at ￡1 mg/L against 50% of the members of b-lactamase-producing Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter spp., and Morganella morganii. Cefpodoxime proved to be highly inhibitory against groups A, B and G streptococci and Streptococcus pneumoniae (MIC90 <0.015 mg/L). The MICs of cefpodoxime and those of the other cephalosporins were <2 mg/L for >90% of the strains of Staphylococcus aureus and Staphylococcus epidermidis, with the exception of cefixime, which had no activity with MICs <8 mg/L against these bacteria. Pseudomonas spp., Acinetobacter spp., and Enterococcus spp., were resistant to cefpodoxime. The antibacterial activity of cefpodoxime was only to a minor degree influenced by different growth conditions, with the exception of high inoculum sizes against some b-lactamase-producing strains of gram-neg. bacilli. In view of the reported in vitro antimicrobial activity of cefpodoxime, its prodrug cefpodoxime proxetil after oral administration is expected to be very useful for the treatment of patients with respiratory and urinary tract infections. .